Glioblastoma Multiforme — Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Citation(s)
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy